You are now leaving Kedrion Corporate site. Medical information including licensed uses may be different outside of the EU countries.
NO
YES
NEWS / EVENTS / .........

EVENTS - 15-05-2015

Kedrion Continues Global Expansion with Dedication Ceremony at US Facility

Kedrion celebrated with local guests and dignitaries at a dedication ceremony for its facility in Melville, New York.  Among the nearly 150 attendees were New York Assemblyman Chad Lupinacci, President and CEO of Empire State Development Howard Zemsky, New York Giants Defensive Back Josh Gordy, Huntington Councilman Mark Cuthbertson, Italian Consul General Natilia Quintavalle, PPTA President Jan Bult, and family of the late Dr. Vincent Freda, co-developer of the first commercially available anti-D immune globulin.  The program also included a presentation of funds raised by Kedrion to support Holy Name Medical Center in Teaneck, New Jersey.

“I am pleased that Kedrion expanded its operations in Melville, and firmly established itself as an important part of our community,” stated New York Assemblyman, Chad Lupinacci.

“Kedrion is a great addition to the local economy, and it's very exciting that they chose to open their high-tech manufacturing facility in Melville,” said Howard Zemsky, President, CEO and Commissioner of Empire State Development. “The work done at this plant will create and retain 180 jobs; it's a huge win for Long Island."

In 2013, Empire State Development awarded Kedrion $1.5 million in performance-based Excelsior tax credits to assist with infrastructure and capital costs. The support for the project was recommended by the Long Island Regional Economic Development Council.

“We started our activity in the United States of America eleven years ago, opening three collection centers,” stated Paolo Marcucci, Chairman and CEO of Kedrion. “Then in 2011, we reinforced our presence with the acquisition of the United States facility. The growth of Kedrion in this country has been constant and significant year by year so that, in 2014, one third of our revenues came from the USA, which has become our company’s largest market.”

A state-of-the-art production line for the manufacturing of anti-D immunoglobulin was recently completed at the Melville facility.  “The Melville plant integrates itself perfectly into Kedrion’s industrial model,” Paolo Marcucci explained, “strengthening a harmonized network of plants located in several countries and enabling us to grow stronger, thus broadening patients’ access to the plasma-derived treatments that we manufacture.  For that reason, this celebration of our global growth represents a renewed commitment to Keep Life Flowing.  We will continue to engage with local communities as we spread our roots throughout the world.”

For more information please contact: pressoffice@kedrion.com